Moskwa Patryk, Zinn Pascal O, Choi Young Eun, Shukla Sachet A, Fendler Wojciech, Chen Clark C, Lu Jun, Golub Todd R, Hjelmeland Anita, Chowdhury Dipanjan
Department of Radiation Oncology, Division of Genomic Stability and DNA Repair, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Department of Internal Medicine A, Medical University of Greifswald, Ferdinand-Sauerbruchstrasse, Greifswald, Germany.
Department of Neurosurgery, Baylor College of Medicine and M Anderson Cancer Center, Houston, Texas.
Mol Cancer Res. 2014 Dec;12(12):1767-78. doi: 10.1158/1541-7786.MCR-14-0268. Epub 2014 Sep 25.
The efficacy of radiotherapy in many tumor types is limited by normal tissue toxicity and by intrinsic or acquired radioresistance. Therefore, it is essential to understand the molecular network responsible for regulating radiosensitivity/resistance. Here, an unbiased functional screen identified four microRNAs (miR1, miR125a, miR150, and miR425) that induce radioresistance. Considering the clinical importance of radiotherapy for patients with glioblastoma, the impact of these miRNAs on glioblastoma radioresistance was investigated. Overexpression of miR1, miR125a, miR150, and/or miR425 in glioblastoma promotes radioresistance through upregulation of the cell-cycle checkpoint response. Conversely, antagonizing with antagomiRs sensitizes glioblastoma cells to irradiation, suggesting their potential as targets for inhibiting therapeutic resistance. Analysis of glioblastoma datasets from The Cancer Genome Atlas (TCGA) revealed that these miRNAs are expressed in glioblastoma patient specimens and correlate with TGFβ signaling. Finally, it is demonstrated that expression of miR1 and miR125a can be induced by TGFβ and antagonized by a TGFβ receptor inhibitor. Together, these results identify and characterize a new role for miR425, miR1, miR125, and miR150 in promoting radioresistance in glioblastomas and provide insight into the therapeutic application of TGFβ inhibitors in radiotherapy.
Systematic identification of miRs that cause radioresistance in gliomas is important for uncovering predictive markers for radiotherapy or targets for overcoming radioresistance.
许多肿瘤类型中放疗的疗效受到正常组织毒性以及内在或获得性放射抗性的限制。因此,了解负责调节放射敏感性/抗性的分子网络至关重要。在此,一项无偏倚的功能筛选鉴定出四种诱导放射抗性的微小RNA(miR1、miR125a、miR150和miR425)。考虑到放疗对胶质母细胞瘤患者的临床重要性,研究了这些微小RNA对胶质母细胞瘤放射抗性的影响。胶质母细胞瘤中miR1、miR125a、miR150和/或miR425的过表达通过上调细胞周期检查点反应促进放射抗性。相反,用抗-miR进行拮抗可使胶质母细胞瘤细胞对辐射敏感,表明它们作为抑制治疗抗性靶点的潜力。对来自癌症基因组图谱(TCGA)的胶质母细胞瘤数据集的分析显示,这些微小RNA在胶质母细胞瘤患者标本中表达,并与TGFβ信号传导相关。最后,证明miR1和miR125a的表达可由TGFβ诱导,并被TGFβ受体抑制剂拮抗。总之,这些结果确定并表征了miR425、miR1、miR125和miR150在促进胶质母细胞瘤放射抗性中的新作用,并为TGFβ抑制剂在放疗中的治疗应用提供了见解。
系统鉴定导致胶质瘤放射抗性的miR对于发现放疗的预测标志物或克服放射抗性的靶点很重要。